ALXO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALXO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. ALX Oncology Holdings's Pre-Tax Income for the three months ended in Mar. 2024 was $-35.58 Mil. ALX Oncology Holdings's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, ALX Oncology Holdings's pretax margin for the quarter that ended in Mar. 2024 was %.
The historical rank and industry rank for ALX Oncology Holdings's Pretax Margin % or its related term are showing as below:
The historical data trend for ALX Oncology Holdings's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Pretax Margin % | Get a 7-Day Free Trial | -400.52 | -3,849.32 | - | - | - |
ALX Oncology Holdings Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Pretax Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, ALX Oncology Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where ALX Oncology Holdings's Pretax Margin % falls into.
Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.
ALX Oncology Holdings's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as
Pretax Margin | = | Pre-Tax Income (A: Dec. 2023 ) | / | Revenue (A: Dec. 2023 ) |
= | -160.805 | / | 0 | |
= | % |
ALX Oncology Holdings's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
Pretax Margin | = | Pre-Tax Income (Q: Mar. 2024 ) | / | Revenue (Q: Mar. 2024 ) |
= | -35.581 | / | 0 | |
= | % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALX Oncology Holdings (NAS:ALXO) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Thank you for viewing the detailed overview of ALX Oncology Holdings's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Shelly Pinto | officer: VP, Finance and CAO | 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010 |
Peter S Garcia | officer: Chief Financial Officer | ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010 |
Sophia Randolph | officer: Chief Medical Officer | C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010 |
Jaume Pons | director, officer: President and CEO | C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010 |
J. Scott Garland | director | 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080 |
Itziar Canamasas | director | C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Jason Lettmann | director, 10 percent owner | C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140 |
Lsv Associates, Llc | 10 percent owner | 2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025 |
G. Walmsley Graham | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Goodman Corey S | director, 10 percent owner, other: Executive Chairman | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Rekha Hemrajani | director | 3928 POINT EDEN WAY, HAYWARD CA 94545 |
Venbio Global Strategic Fund, L.p. | 10 percent owner, other: See Remarks | 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
Vivo Opportunity Fund, L.p. | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Vivo Opportunity, Llc | 10 percent owner | 192 LYTTON AVENUE, PALO ALTO CA 94301 |
Steffen Pietzke | officer: VP Fin & Chief Acct Officer | C/O ENOVIX CORPORATION, 3501 W. WARREN AVENUE, FREMONT CA 94538 |
From GuruFocus
By Marketwired • 08-10-2023
By Marketwired • 08-31-2023
By Value_Insider Value_Insider • 11-29-2022
By Marketwired • 09-06-2023
By Ds*** Ds*** • 09-01-2022
By sperokesalga sperokesalga • 02-16-2023
By sperokesalga sperokesalga • 05-09-2023
By PurpleRose PurpleRose • 08-08-2022
By GuruFocus Research • 11-13-2023
By Stock market mentor Stock market mentor • 01-05-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.